Jazz Pharmaceuticals plc (NASDAQ:JAZZ) went up by 8.97% from its latest closing price compared to the recent 1-year high of $189.00. The company’s stock price has collected 11.82% of gains in the last five trading sessions. Press Release reported 12 hours ago that Thinking about trading options or stock in Jazz Pharmaceuticals, ViacomCBS, Progressive, Tesla, or Exxon Mobil?
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ :JAZZ) Right Now?
Plus, the 36-month beta value for JAZZ is at 0.93.
JAZZ currently public float of 59.89M and currently shorts hold a 7.37% ratio of that float. Today, the average trading volume of JAZZ was 554.86K shares.
JAZZ’s Market Performance
JAZZ stocks went up by 11.82% for the week, with a monthly jump of 19.01% and a quarterly performance of 7.18%, while its annual performance rate touched -9.52%. The volatility ratio for the week stands at 3.26% while the volatility levels for the past 30 days are set at 2.88% for Jazz Pharmaceuticals plc. The simple moving average for the period of the last 20 days is 14.79% for JAZZ stocks with a simple moving average of -3.36% for the last 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Goldman repeating the rating for JAZZ by listing it as a “Buy.” The predicted price for JAZZ in the upcoming period, according to Goldman is $198 based on the research report published on November 19th of the previous year 2021.
Jefferies, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $172. The rating they have provided for JAZZ stocks is “Buy” according to the report published on October 07th, 2021.
Citigroup gave a rating of “Buy” to JAZZ, setting the target price at $200 in the report published on October 05th of the previous year.
JAZZ Trading at 13.48% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.49% of loss for the given period.
Volatility was left at 2.88%, however, over the last 30 days, the volatility rate increased by 3.26%, as shares surge +19.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.41% upper at present.
During the last 5 trading sessions, JAZZ rose by +11.82%, which changed the moving average for the period of 200-days by -13.02% in comparison to the 20-day moving average, which settled at $128.81. In addition, Jazz Pharmaceuticals plc saw 14.98% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at JAZZ starting from COZADD BRUCE C, who sale 5,791 shares at the price of $127.85 back on Jan 03. After this action, COZADD BRUCE C now owns 322,460 shares of Jazz Pharmaceuticals plc, valued at $740,387 using the latest closing price.
Smith Mark Douglas, the Director of Jazz Pharmaceuticals plc, sale 417 shares at $121.30 during a trade that took place back on Dec 02, which means that Smith Mark Douglas is holding 4,419 shares at $50,582 based on the most recent closing price.
Stock Fundamentals for JAZZ
Equity return is now at value -4.10, with -1.70 for asset returns.